# Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

> **NCT03748186** · PHASE1 · COMPLETED · sponsor: **Sutro Biopharma, Inc.** · enrollment: 136 (actual)

## Conditions studied

- Ovarian Cancer
- Ovarian Carcinoma
- Ovary Cancer
- Endometrial Cancer
- Endometrioid Adenocarcinoma
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** STRO-002

## Key facts

- **NCT ID:** NCT03748186
- **Lead sponsor:** Sutro Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-01
- **Primary completion:** 2024-06-04
- **Final completion:** 2024-06-04
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03748186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03748186, "Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03748186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*